The 21st century technology revolution has the power to reshape the way organizations manage, process, and harness data, drive innovation, and unlock new possibilities for consumers and patients across the globe
Evaluation of Pharmacokinetics of a BCS Class III Drug with Two Different Study Designs: Tenofovir Alafenamide Monofumarate Film-coated Tablet
Tenofovir alafenamide (TAF) is a BCS Class III compound and an oral pro-drug of Tenofovir (TFV) with limited oral bioavailability.
Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes
Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy.
Building Patient Trust with Next-Generation Clinical Trial Training
Patient trust is critical to ensuring adequate enrollment and retention of clinical trial participants.
Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations
The use of in vitro-in vivo correlation (IVIVC) for extended release oral dosage forms is an important technique that can avoid potential clinical studies.
Construction of a physiologically based pharmacokinetic model of paclobutrazol and exposure estimation in the human body
Paclobutrazol (PBZ) is a plant growth regulator that can delay plant growth and improve plant resistance and yield. Although it has been widely used in the growth of medicinal plants, human beings may take it by taking traditional Chinese medicine.
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets
The United States Food and Drug Administration guidelines for the bioequivalence (BE) testing of the generic drug products suggests that there should be an equal proportion of male and female population in the BE study.
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Monolix Comparison Flyer
Your software should make it easier to conduct non-compartmental, bioequivalence and compartmental analysis and use that data to make the right decisions for your program.
Regulatory Strategies Flyer
Get to Market Faster with Robust Regulatory Strategies
Clinical Pharmacology & Pharmacometrics Software and Services Flyer
Supporting Dose Selection and Justification
Cheminformatics Software & Services Flyer
Understand Your Compound
PBPK Software and Services Flyer
Optimize Decision Making Throughout R&D with PBPK Predictions
Integrating Human Biomimetic Liver Microphysiology System with Quantitative Systems Toxicology Modeling to Predict DILI
Integrating Human Biomimetic Liver Microphysiology System with Quantitative Systems Toxicology Modeling to Predict DILI
Demystifying GPX™ Installation: Expert Insights and Practical Tips
Get ready to turbocharge your scientific team’s PBBM PBPK modeling technology with the latest version of GastroPlus®!
GPX™ The Next Level PBPK Platform
It’s here—the latest version of GastroPlus®, GPX. And this is your chance to see it in action.
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations
The equivalence of absorption rates and extents between generic drugs and their reference formulations is crucial for ensuring therapeutic comparability.
GastroPlus®X (GPX™) Product Brochure
GastroPlus X (GPX™) is a mechanistically based simulation software package that simulates intravenous and oral absorption, pharmacokinetics, drug-drug interactions and pharmacodynamics in humans and animals.